/PRNewswire/ Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today confirms it has received preliminary approval from the.
Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Hikma and GSK agree to cease potential acquisition investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
About Hikma Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody s) Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people s lives. We re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthie